tiprankstipranks
Trending News
More News >
Barinthus Biotherapeutics (BRNS)
NASDAQ:BRNS
Advertisement

Barinthus Biotherapeutics (BRNS) AI Stock Analysis

Compare
97 Followers

Top Page

BRNS

Barinthus Biotherapeutics

(NASDAQ:BRNS)

Rating:46Neutral
Price Target:
$1.00
▼(-15.25% Downside)
Barinthus Biotherapeutics faces significant financial challenges with ongoing losses and cash flow issues, which are the most impactful factors in the overall score. The technical analysis indicates neutral to bearish momentum, while the valuation is unattractive due to a negative P/E ratio and no dividend yield.
Positive Factors
Clinical Trials
The ongoing first-in-human Phase 1 AVALON trial of VTP-1000 has shown no treatment-related serious adverse events in the first two cohorts, which is promising for the drug's safety profile.
Financial Stability
The company has a cash runway into 2027, providing a stable financial foundation to support continued research and development efforts.
Negative Factors
Competition
The competitive landscape for celiac disease treatment includes major players like Sanofi and Teva, which are advancing their Phase 2 trials.
Financial Performance
The net loss of $21.2M was significantly higher than the estimated loss of $11.8M, which could raise concerns about financial performance.

Barinthus Biotherapeutics (BRNS) vs. SPDR S&P 500 ETF (SPY)

Barinthus Biotherapeutics Business Overview & Revenue Model

Company DescriptionBarinthus Biotherapeutics (BRNS) is a biotechnology company specializing in the development of innovative therapeutic solutions aimed at addressing unmet medical needs. Operating primarily in the biopharmaceutical sector, Barinthus focuses on the research and development of novel biologics and advanced drug delivery systems. The company's core products include a range of targeted therapies designed to treat various chronic and life-threatening diseases.
How the Company Makes MoneyBarinthus Biotherapeutics generates revenue through a multifaceted business model that includes product sales, licensing agreements, and strategic partnerships. The company earns income from the commercialization of its proprietary therapies, which are sold to healthcare providers and institutions. Additionally, Barinthus licenses its technologies and drug candidates to other pharmaceutical companies, earning royalty payments and milestone fees. The company also engages in collaborative research and development partnerships, which provide funding and shared revenue opportunities. These collaborations often include co-development and co-marketing agreements that further enhance Barinthus's financial position.

Barinthus Biotherapeutics Financial Statement Overview

Summary
Barinthus Biotherapeutics is experiencing financial challenges with ongoing losses and cash flow issues, despite improvements in revenue and gross profit margins. The balance sheet is stable, but the company needs to focus on achieving profitability and improving cash flow.
Income Statement
45
Neutral
Barinthus Biotherapeutics has shown significant volatility in its revenue and profitability. The revenue growth from 2023 to 2024 was substantial, but the company remains unprofitable with negative net income and EBIT margins. The gross profit margin improved in 2024, indicating better cost management, but the overall financial health is hindered by persistent losses.
Balance Sheet
55
Neutral
The company's balance sheet reflects a strong equity position with a high equity ratio, indicating stability. However, the debt-to-equity ratio is relatively low, suggesting manageable leverage. The decline in stockholders' equity over the years is a concern, but the reduction in total liabilities is a positive sign.
Cash Flow
40
Negative
Cash flow analysis reveals challenges with negative operating and free cash flows, indicating potential liquidity issues. The free cash flow has improved slightly from 2023 to 2024, but the company continues to burn cash, which could be a risk if not addressed.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue14.97M14.97M802.00K44.70M268.00K4.82M
Gross Profit-1.17M14.97M-4.64M44.70M268.00K4.82M
EBITDA-62.56M-55.37M-71.06M6.40M-47.87M-14.03M
Net Income-69.42M-61.07M-73.35M5.34M-50.87M-17.71M
Balance Sheet
Total Assets129.56M160.33M214.51M270.20M280.71M50.67M
Cash, Cash Equivalents and Short-Term Investments86.26M110.66M142.09M194.38M214.05M43.27M
Total Debt11.99M12.01M12.98M8.77M7.22M46.36M
Total Liabilities27.08M30.19M27.51M27.00M28.15M87.58M
Stockholders Equity102.38M130.03M186.78M242.90M252.13M-37.30M
Cash Flow
Free Cash Flow-38.54M-29.83M-56.34M-20.57M-33.73M-11.32M
Operating Cash Flow-38.12M-28.94M-50.92M-14.43M-32.58M-11.03M
Investing Cash Flow-429.22K-892.00K-5.41M-5.75M-12.91M-293.00K
Financing Cash Flow1.30M2.16M1.87M325.00K222.74M41.44M

Barinthus Biotherapeutics Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price1.18
Price Trends
50DMA
1.21
Negative
100DMA
1.04
Positive
200DMA
1.04
Positive
Market Momentum
MACD
-0.04
Positive
RSI
45.43
Neutral
STOCH
32.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRNS, the sentiment is Neutral. The current price of 1.18 is below the 20-day moving average (MA) of 1.30, below the 50-day MA of 1.21, and above the 200-day MA of 1.04, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 45.43 is Neutral, neither overbought nor oversold. The STOCH value of 32.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BRNS.

Barinthus Biotherapeutics Risk Analysis

Barinthus Biotherapeutics disclosed 101 risk factors in its most recent earnings report. Barinthus Biotherapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Barinthus Biotherapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.88B-0.12-39.83%2.18%21.38%-1.56%
46
Neutral
$47.61M-53.78%-5.42%
45
Neutral
$62.74M-87.74%-60.16%
44
Neutral
$30.52M-78.25%248.62%26.22%
41
Neutral
$21.70M-24.97%38.80%
40
Underperform
$26.19M-42.65%-10.95%
39
Underperform
$62.65M-104.21%39.60%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BRNS
Barinthus Biotherapeutics
1.18
-0.06
-4.84%
CLGN
Collplant Holdings
2.52
-2.58
-50.59%
ALXO
ALX Oncology Holdings
1.17
-1.40
-54.47%
ALGS
Aligos Therapeutics
10.20
-3.16
-23.65%
GDTC
CytoMed Therapeutics Limited
1.85
0.40
27.59%
BOLD
Boundless Bio Inc.
1.17
-2.76
-70.23%

Barinthus Biotherapeutics Corporate Events

Executive/Board ChangesShareholder MeetingsDividends
Barinthus Biotherapeutics Approves Key Proposals at AGM
Neutral
Jun 10, 2025

On June 10, 2025, Barinthus Biotherapeutics held its Annual General Meeting where all proposed matters were approved, including the re-election of directors and the appointment of auditors. The meeting also covered financial matters such as the approval of the directors’ remuneration policy and the decision not to pay dividends for the fiscal year ending December 31, 2024.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 20, 2025